X4 Pharmaceuticals Files 8-K for Regulation FD Disclosure
Ticker: XFOR · Form: 8-K · Filed: Aug 9, 2024 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | 8-K |
| Filed Date | Aug 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulation-fd
TL;DR
X4 Pharma dropped an 8-K, likely some material news for investors.
AI Summary
X4 Pharmaceuticals, Inc. filed an 8-K on August 9, 2024, reporting a Regulation FD Disclosure as of August 8, 2024. The filing does not contain specific details about the nature of the disclosure, but it is a standard current report for material events.
Why It Matters
This filing indicates that X4 Pharmaceuticals has made a disclosure under Regulation FD, which requires public companies to disclose material non-public information to all investors simultaneously.
Risk Assessment
Risk Level: medium — While the filing itself is routine, the underlying event triggering the 8-K could be significant, requiring investors to seek further details.
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- August 8, 2024 (date) — Date of earliest event reported
- August 9, 2024 (date) — Date of report
- Regulation FD (regulation) — Type of disclosure
FAQ
What specific information was disclosed under Regulation FD?
The provided filing is a Form 8-K indicating a Regulation FD Disclosure, but the specific details of the disclosure are not included in this excerpt.
When was the earliest event reported in this 8-K?
The earliest event reported was on August 8, 2024.
What is the primary purpose of a Form 8-K filing?
A Form 8-K is used by publicly traded companies to announce major corporate events that shareholders should know about.
What is the principal executive office address for X4 Pharmaceuticals, Inc.?
The principal executive offices are located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.
What is the IRS Employer Identification Number for X4 Pharmaceuticals, Inc.?
The IRS Employer Identification Number is 27-3181608.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-08-09 16:28:20
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market
Filing Documents
- xfor-20240808.htm (8-K) — 26KB
- 0001628280-24-036495.txt ( ) — 152KB
- xfor-20240808.xsd (EX-101.SCH) — 2KB
- xfor-20240808_lab.xml (EX-101.LAB) — 23KB
- xfor-20240808_pre.xml (EX-101.PRE) — 13KB
- xfor-20240808_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On August 8, 2024, X4 Pharmaceuticals, Inc. (the "Company") posted an updated corporate presentation on the Company's website. To access the presentation, investors should visit the "Investors" section of the Company's website at www.x4pharma.com. The information furnished under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: August 8, 2024 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer